Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 22 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 22 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Sodium chloride (0.9%) provides isotonic concentration of sodium and chloride ions to maintain extracellular fluid volume and osmolarity. Potassium chloride (0.22%) provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; typical adult dose is 1-2 L over 24 hours, titrated to fluid and electrolyte needs. Maximum rate 1 L/hour under controlled conditions.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable (endogenous substances); distribution half-life ~1–2 hours for infused dose; clinical context: no true elimination half-life due to homeostatic regulation; steady-state achieved with continuous infusion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: Sodium >95% (glomerular filtration and variable tubular reabsorption); Potassium >90% (glomerular filtration and tubular secretion/reabsorption). Fecal <5%.
Category C
Category A/B
Electrolyte
Electrolyte